Literature DB >> 26922172

Vaccines in Multiple Sclerosis.

Eric M L Williamson1, Salim Chahin2, Joseph R Berger3.   

Abstract

Vaccinations help prevent communicable disease. To be valuable, a vaccine's ability to prevent disease must exceed the risk of adverse effects from administration. Many vaccines present no risk of infection as they are comprised of killed or non-infectious components while other vaccines consist of live attenuated microorganisms which carry a potential risk of infection-particularly, in patients with compromised immunity. There are several unique considerations with respect to vaccination in the multiple sclerosis (MS) population. First, there has been concern that vaccination may trigger or aggravate the disease. Second, disease-modifying therapies (DMTs) employed in the treatment of MS may increase the risk of infectious complications from vaccines or alter their efficacy. Lastly, in some cases, vaccination strategies may be part of the treatment paradigm in attempts to avoid complications of therapy.

Entities:  

Keywords:  Disease-modifying therapy; Immunity; Influenza; Multiple sclerosis; Vaccination; Varicella zoster

Mesh:

Substances:

Year:  2016        PMID: 26922172     DOI: 10.1007/s11910-016-0637-6

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  50 in total

1.  Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis.

Authors:  G Ristori; M G Buzzi; U Sabatini; E Giugni; S Bastianello; F Viselli; C Buttinelli; S Ruggieri; C Colonnese; C Pozzilli; M Salvetti
Journal:  Neurology       Date:  1999-10-22       Impact factor: 9.910

2.  The risk of relapses in multiple sclerosis during systemic infections.

Authors:  Jorge Correale; Marcela Fiol; Wendy Gilmore
Journal:  Neurology       Date:  2006-07-26       Impact factor: 9.910

3.  CNS demyelination and quadrivalent HPV vaccination.

Authors:  I Sutton; R Lahoria; Il Tan; P Clouston; Mh Barnett
Journal:  Mult Scler       Date:  2008-09-19       Impact factor: 6.312

4.  Detection of antinuclear antibody in the serum of patients with multiple sclerosis.

Authors:  V K Singh
Journal:  Immunol Lett       Date:  1982-06       Impact factor: 3.685

5.  Vaccinations and risk of central nervous system demyelinating diseases in adults.

Authors:  Frank DeStefano; Thomas Verstraeten; Lisa A Jackson; Catherine A Okoro; Patti Benson; Steven B Black; Henry R Shinefield; John P Mullooly; William Likosky; Robert T Chen
Journal:  Arch Neurol       Date:  2003-04

Review 6.  Infection risk in patients on multiple sclerosis therapeutics.

Authors:  Eric M Williamson; Joseph R Berger
Journal:  CNS Drugs       Date:  2015-03       Impact factor: 5.749

7.  Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis.

Authors:  J De Keyser; C Zwanikken; M Boon
Journal:  J Neurol Sci       Date:  1998-07-15       Impact factor: 3.181

8.  Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab.

Authors:  Jennifer Yeung; Cécile Cauquil; Guillaume Saliou; Ghaida Nasser; Sophio Rostomashvili; David Adams; Marie Théaudin
Journal:  Neurology       Date:  2013-04-24       Impact factor: 9.910

9.  Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis.

Authors:  Michael Kaufman; Gabriel Pardo; Howard Rossman; Marianne T Sweetser; Fiona Forrestal; Petra Duda
Journal:  J Neurol Sci       Date:  2014-03-26       Impact factor: 3.181

10.  Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens.

Authors:  Amit Bar-Or; Heinz Wiendl; Barry Miller; Myriam Benamor; Philippe Truffinet; Meg Church; Francoise Menguy-Vacheron
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-02-12
View more
  9 in total

1. 

Authors:  Norbert Wagner; Frauke Assmus; Gabriele Arendt; Erika Baum; Ulrich Baumann; Christian Bogdan; Gerd Burchard; Dirk Föll; Edeltraut Garbe; Jane Hecht; Ulf Müller-Ladner; Tim Niehues; Klaus Überla; Sabine Vygen-Bonnet; Thomas Weinke; Miriam Wiese-Posselt; Michael Wojcinski; Fred Zepp
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2019-04       Impact factor: 1.513

2.  COVID-19 mRNA vaccination leading to CNS inflammation: a case series.

Authors:  Mahsa Khayat-Khoei; Shamik Bhattacharyya; Joshua Katz; Daniel Harrison; Shahamat Tauhid; Penny Bruso; Maria K Houtchens; Keith R Edwards; Rohit Bakshi
Journal:  J Neurol       Date:  2021-09-04       Impact factor: 6.682

3.  Vaccine Hesitancy in Patients With Multiple Sclerosis: Preparing for the SARS-CoV-2 Vaccination Challenge.

Authors:  Lara Diem; Christoph Friedli; Andrew Chan; Anke Salmen; Robert Hoepner
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-04-02

Review 4.  Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide.

Authors:  Carlo Tornatore; Heinz Wiendl; Alex L Lublin; Svend S Geertsen; Jeffrey Chavin; Philippe Truffinet; Amit Bar-Or
Journal:  Front Neurol       Date:  2022-02-28       Impact factor: 4.003

5.  Expert-Agreed Practical Recommendations on the Use of Cladribine.

Authors:  Virginia Meca-Lallana; José M García Domínguez; Rocío López Ruiz; Jesús Martín-Martínez; Adrián Arés Luque; Miguel A Hernández Pérez; José M Prieto González; Lamberto Landete Pascual; Jaume Sastre-Garriga
Journal:  Neurol Ther       Date:  2022-09-06

Review 6.  Pollution, Inflammation, and Vaccines: A Complex Crosstalk.

Authors:  Laura Franza; Rossella Cianci
Journal:  Int J Environ Res Public Health       Date:  2021-06-11       Impact factor: 3.390

Review 7.  Frequently asked questions on seven rare adverse events following immunization.

Authors:  G L D'alò; E Zorzoli; A Capanna; G Gervasi; E Terracciano; L Zaratti; E Franco
Journal:  J Prev Med Hyg       Date:  2017-03

8.  A matched case-control study of risk factors associated with multiple sclerosis in Kuwait.

Authors:  Hadeel El-Muzaini; Saeed Akhtar; Raed Alroughani
Journal:  BMC Neurol       Date:  2020-02-21       Impact factor: 2.474

9.  Immune response to vaccines is maintained in patients treated with dimethyl fumarate.

Authors:  Christian von Hehn; Jonathan Howard; Shifang Liu; Ven Meka; Joe Pultz; Devangi Mehta; Claudia Prada; Soma Ray; Michael R Edwards; Sarah I Sheikh
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-11-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.